Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02653157
Other study ID # 15-1505
Secondary ID US NIH Grant KL2
Status Completed
Phase
First received
Last updated
Start date October 2015
Est. completion date December 2017

Study information

Verified date October 2018
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective observational study to determine the role of colonization and identify the timing of development of drug resistance in multidrug resistant Gram-negative bacilli (MDR-GNB) causing infection among critically ill burn patients.


Description:

This is a prospective observational study. Patients will be followed during a single admission for development of colonization or infection with MDR-GNB. Patient clinical characteristics, including infections, surgeries, and antibiotic exposure, will be collected in real-time.

Weekly surveillance wound and peri-rectal swabs and, if intubated, biweekly deep endotracheal or tracheostomy aspirates will be collected, de-identified, and stored from all patients and examined for the presence of MDR-GNB. All GNB isolates from blood, urine, respiratory, and wound cultures will be collected, coded, and stored.


Recruitment information / eligibility

Status Completed
Enrollment 48
Est. completion date December 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Severe burn injury, including partial or full thickness burn 20% or more total body surface area; or

2. inhalation injury; or

3. 18 years of age or older;

Exclusion Criteria:

1. Intensive care unit stay of less than 5 days;

2. ICU admission more than 48 hours after burn trauma.

Study Design


Related Conditions & MeSH terms

  • Infection
  • Multi-drug Resistant Gram-negative Bacilli Colonization

Intervention

Other:
MDR-GNB


Locations

Country Name City State
United States University of North Carolina Jaycee Burn Center Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill North Carolina Translational and Clinical Sciences Institute

Country where clinical trial is conducted

United States, 

References & Publications (17)

American Burn Association. National Burn Repository 2014 Report. Available at http://www.ameriburn.org/2014NBRAnnualReport.pdf. Accessed December 23, 2014.

American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416. — View Citation

Brusselaers N, Labeau S, Vogelaers D, Blot S. Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. Intensive Care Med. 2013 Mar;39(3):365-75. doi: 10.1007/s00134-012-2759-x. Epub 2012 Nov 28. Review. — View Citation

Brusselaers N, Logie D, Vogelaers D, Monstrey S, Blot S. Burns, inhalation injury and ventilator-associated pneumonia: value of routine surveillance cultures. Burns. 2012 May;38(3):364-70. doi: 10.1016/j.burns.2011.09.005. Epub 2011 Oct 29. — View Citation

Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at http://www.cdc.gov/drugresistance/threat-report-2013 Accessed December 23, 2014.

Craven DE, Hjalmarson KI. Ventilator-associated tracheobronchitis and pneumonia: thinking outside the box. Clin Infect Dis. 2010 Aug 1;51 Suppl 1:S59-66. doi: 10.1086/653051. Review. Erratum in: Clin Infect Dis. 2010 Nov 1;51(9):1114. — View Citation

de La Cal MA, Cerdá E, García-Hierro P, Lorente L, Sánchez-Concheiro M, Díaz C, van Saene HK. Pneumonia in patients with severe burns : a classification according to the concept of the carrier state. Chest. 2001 Apr;119(4):1160-5. — View Citation

Lachiewicz AM, van Duin D, DiBiase LM, Jones SW, Carson S, Rutala WA, Cairns BA, Weber DJ. Rates of hospital-associated respiratory infections and associated pathogens in a regional burn center, 2008-2012. Infect Control Hosp Epidemiol. 2015 May;36(5):601-3. doi: 10.1017/ice.2014.90. Epub 2015 Jan 28. — View Citation

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27. — View Citation

Mosier MJ, Pham TN. American Burn Association Practice guidelines for prevention, diagnosis, and treatment of ventilator-associated pneumonia (VAP) in burn patients. J Burn Care Res. 2009 Nov-Dec;30(6):910-28. doi: 10.1097/BCR.0b013e3181bfb68f. — View Citation

Rue LW 3rd, Cioffi WG, Mason AD Jr, McManus WF, Pruitt BA Jr. The risk of pneumonia in thermally injured patients requiring ventilatory support. J Burn Care Rehabil. 1995 May-Jun;16(3 Pt 1):262-8. — View Citation

Shirani KZ, Pruitt BA Jr, Mason AD Jr. The influence of inhalation injury and pneumonia on burn mortality. Ann Surg. 1987 Jan;205(1):82-7. — View Citation

Siegel JD, Rhinehart E, Jackson M, et al. Management of multidrug-resistant organisms in healthcare settings, 2006. Available at http://www.cdc.gov/hicpac/pdf/MDRO/MDROGuideline2006.pdf. Accessed December 23, 2014.

Sievert DM, Ricks P, Edwards JR, Schneider A, Patel J, Srinivasan A, Kallen A, Limbago B, Fridkin S; National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14. doi: 10.1086/668770. Epub 2012 Nov 27. — View Citation

Tedja R, Nowacki A, Fraser T, Fatica C, Griffiths L, Gordon S, Isada C, van Duin D. The impact of multidrug resistance on outcomes in ventilator-associated pneumonia. Am J Infect Control. 2014 May;42(5):542-5. doi: 10.1016/j.ajic.2013.12.009. Epub 2014 Mar 14. — View Citation

Weber DJ, van Duin D, DiBiase LM, Hultman CS, Jones SW, Lachiewicz AM, Sickbert-Bennett EE, Brooks RH, Cairns BA, Rutala WA. Healthcare-associated infections among patients in a large burn intensive care unit: incidence and pathogens, 2008-2012. Infect Control Hosp Epidemiol. 2014 Oct;35(10):1304-6. doi: 10.1086/678067. Epub 2014 Sep 2. — View Citation

Wibbenmeyer L, Danks R, Faucher L, Amelon M, Latenser B, Kealey GP, Herwaldt LA. Prospective analysis of nosocomial infection rates, antibiotic use, and patterns of resistance in a burn population. J Burn Care Res. 2006 Mar-Apr;27(2):152-60. — View Citation

* Note: There are 17 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary Species causing MDR-GNB colonization Endotracheal tube or tracheostomy aspirates will be obtained upon admission and twice weekly; wound and perirectal area swabs will be collected weekly and will be used to characterize species. From hospital admission through length of hospital stay, or date of death from any cause, whichever comes first (assessed up to 52 weeks)
Primary Time to MDR-GNB colonization surveillance samples for bacterial colonization will be collected weekly From hospital admission until discharge from unit, or date of death from any cause (assessed up to 1 year)
Primary Time to development of MDR and extreme drug resistant bacteria surveillance samples will be collected weekly From hospital admission until date of development of MDR or extremely drug resistant bacteria (assessed up to 52 weeks)
Primary Time to VAT/VAP defined by bacteria obtained from clinical bronchoscopy and patient symptoms as noted by chart review Time of hospital admission until date of development of VAT/VAP or date of death from any cause (assessed up to 52 weeks)
Primary Time to MDR-GNB VAT/VAP From hospital admission until date of development of MDR-GNB VAT/VAP or date of death from any cause (assessed up to 52 weeks)